Results 151 to 160 of about 1,977,916 (307)

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness? [PDF]

Brian J. Piper, Maria Tian, Pragosh Saini, Ahmad Higazy, Jason Graham, Christian Carbe, Michael Bordonaro   +6 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study [PDF]

, 2016
Sauzanne Khalilieh, Ka Lai Yee, Rosa I. Sánchez, Ilias Triantafyllou, Fan Li, Noha Maklad, Heather R. Jordan, Maureen Martell, Marian Iwamoto   +8 more
openalex   +1 more source

Kernel methods for in silico chemogenomics

, 2007
Predicting interactions between small molecules and proteins is a crucial ingredient of the drug discovery process. In particular, accurate predictive models are increasingly used to preselect potential lead compounds from large molecule databases, or to
Jacob, Laurent, Vert, Jean-Philippe
core   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Isobolographic analysis of the sedative interaction between six central nervous system depressant drugs and Valeriana edulis hydroalcoholic extract in mice* [PDF]

, 2005
M. Ugalde, Victoria Reza, Ma. Eva González‐Trujano, Bharathi Avula, Ikhlas A. Khan, Andrés Navarrete   +5 more
openalex   +1 more source

European Code Against Cancer, 5th edition – hormone replacement therapy, other common medical therapies and cancer

Molecular Oncology, EarlyView.
The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations regarding the use of hormone replacement therapy (HRT), which is positioned as recommendation number 13 of the ECAC5.
Mangesh A. Thorat, Marc Arbyn, David Baldwin, Xavier Castells, Solveig Hofvind, Urska Ivanus, Carlo Senore, Esther Toes‐Zoutendijk, Carlijn van der Aalst, Carlos Canelo‐Aybar, Fiorella Karina Fernández‐Sáenz, Ariadna Feliu, Hajo Zeeb, Andre L. Carvalho, Erica D'Souza, David Ritchie, Carolina Espina, Iris Lansdorp‐Vogelaar, Andrea DeCensi   +18 more
wiley   +1 more source

Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101 [PDF]

, 2023
Chun‐Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, Tung‐Yi Lin, Muh‐Hwa Yang, Jeffrey W. Dalley, Tung‐Hu Tsai   +6 more
openalex   +1 more source